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Abstract
Background: Helicobacter pylori, occurring throughout the world and causing gastroduodenal
diseases, is one of the most common chronic bacterial agents in humans. The purpose of this study
was to measure the general practitioners' (GPs) knowledge and practices pertaining to H. pylori
infection.
Methods: A cross-sectional type questionnaire survey was conducted in all of 19 primary health
care centres (PHCC) in Samsun, Turkey, between November 1 and December 31, 2003. The
questionnaire was sent to 124 GPs and 109 (87.9 %) of those filled in. They were requested to
answer the questions on the knowledge, sources of medical information, diagnostic tests and
treatment to H. pylori.
Results: Medical journals were the most frequently used source of information on H. pylori, being
cited by 86 (78.9%) of GPs. Ninety-two (84.4%) of the GPs reported having used one or more tests
and 17 (15.6%) never used any test for the diagnosis of H. pylori infection. Only 9.8% had used stool
antigen test for diagnosis. GPs reported that they would prescribe symptomatic treatment without
ordering diagnostic tests for 29 (26.6%). 54.1% of the GPs explain that they sent patients with H.
pylori infection to a specialist, and most used a triple drug regimen containing a PPI. Treatment
duration varies between 7 to 28 days. 80.7 of the GPs treat patients for 14 days.
Conclusion: GPs may not have enough knowledge about the importance of stool antigen test or
possibility of usage of this test. GPs have not sufficient knowledge about the difference between
symptomatic and asymptomatic individuals. It is thought that GPs preferred to treat the patients
with suspected ulcer empirically or to send them to a specialist because of the limited diagnostic
conditions. The efforts to educate the GPs about the algorithms regarding the management of H.
pylori infection during post-graduation period should be improved in PHCCs.
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Helicobacter pylori, occurring throughout the world and
causing gastroduodenal diseases, is one of the most com-
mon chronic bacterial agents in humans [1]. Although the
number of peptic ulcers unrelated to H. pylori is increas-
ing, most ulcers are related to H. pylori infection [2,3]. For
most of the patients with gastrointestinal symptoms apply
to general practitioners (GPs), non-invasive "test and
treat" policies for H. pylori infection have been promoted
in order to improve early detection and treatment of
ulcers in dyspeptic patients [4,5].
The successful isolation of H. pylori infection in patients
with chronic gastritis and peptic ulcer disease in 1983 has
fundamentally changed concept of the etiologic, patho-
genesis and management of upper gastrointestinal (UGI)
diseases [6]. This has led to an explosion of H. pylori
related information and the development and publication
of international, regional and national guidelines [7].
Subsequently, numerous educational initiatives have
been undertaken to educate health care professionals
regarding the appropriate diagnosis and management of
this infection. However, results from several recent sur-
veys conducted in different countries have revealed that
significant confusion exists and discrepancies are present
in the thinking among GPs with respect to the under-
standing of the relationship between H. pylori infection
and the pathogenesis, diagnosis and treatment of UGI dis-
eases [6]. The major uncertainties surround the manage-
ment of patients with dyspepsia where the GPs needs to
make a decision whether to test for H. pylori infection and
treat if positive, and when to refer patients to a specialist
[8,9].
It is thought that too many patients with dyspeptic symp-
toms apply to GPs in Turkey. This study was performed a
survey of GPs' to assess their knowledge and practices per-
taining to H. pylori infection.
Methods
A cross-sectional study was conducted in all of 19 primary
health care centres (PHCC) in Samsun, Turkey, between
November 1 and December 31, 2003. The questionnaire
was sent to all GPs (n = 124). 109 of 124 (87.9 %) GPs
from different PHCCs completed the survey. The material
used was adapted from the questionnaire devised by
Sharma et al. [10] and translated into Turkish. The ques-
tionnaire was designed in a self-administered format with
closed answers being provided to questions. Demo-
graphic variables such as gender, age and working year
were assessed. The survey questionnaire includes a multi-
ple-choice question relevant to sources of medical infor-
mation. The H. pylori knowledge section contained 6
questions. The items assessed respondents' knowledge of
diagnosis of infection, case selection for treatment and
treatment options in H. pylori. Participating GPs were
asked to offer the type(s) of diagnostic tests such as ELISA,
histology, biopsy urease test (BUT), urea breath test (UBT)
or culture of biopsy specimen.
A list of 7 different clinical presentations was given. It was
asked whether the respondents would offer testing for H.
pylori and also treat the infection when the test results
were positive for H. pylori.
The respondents were asked to select a regimen for the
management of H. pylori infection among the list of four
drug combination regimens included proton pump inhib-
itor (PPI)-based triple therapies. [7,11,12]. GPs were also
asked about their choice of treatment duration. The
authors did not make any educational program focusing
on H. pylori infection before or after the survey in this
study period. Data were given as mean ± standard devia-
tion (SD) and percentage.
Results
Sociodemographic characteristics
The mean age and working year of the GPs was 31.7 ± 5.4
and 7.2 ± 5.0 years, respectively; 59 (54.1%) of the GPs
were women.
Sources of information
Medical journals were the most frequently used source of
information on H. pylori, being cited by 86 (78.9%) of
GPs. Pharmaceutical company-sponsored symposia
(70.6%), textbooks (64.2%), conferences (20.2%) and
on-line sites (6.4%) were the other major source of infor-
mation used by the GPs. These numbers add up to more
than 100% because the GPs had been checked more than
one item.
Diagnostic tests for H. pylori
Ninety-two (84.4%) of the GPs reported having used one
or more tests and 17 (15.6%) never used any test for the
diagnosis of H. pylori infection. Of those, 44.1% had used
UBT, 34.5% had used BUT, 23.8 % had used ELISA and
9.8% had used the stool antigen test. The practitioners
included in the survey had not equally access to all diag-
nostic tests mentioned in the study.
Testing and treatment choices for H. pylori infection
The proportions of GPs who would test patients for H.
pylori infection in the 9 different clinical situations and the
proportions of those who would offer treatment based on
a positive test result, were summarized in Table-1. 92
(84.4%) of the GPs answered this section. GPs reported
that they would prescribe symptomatic treatment without
ordering diagnostic tests for 29 (26.6%). 54.1% of the
GPs explain that they send patients with H. pylori infection
to a specialist.Page 2 of 5
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Treatment regimens of choice are listed in Table-2. Most
used a triple drug regimen containing a PPI. Of the GPs
3.7% would treat patients for 7 days, 4.6% for 10 days,
80.7% for 14 days, 3.7% for 21 days, 5.5% for 28 days and
1.8% for more than 28 days.
Discussion
UGI symptoms are common reasons for patients to visit
GPs. In recent years, the development of non-invasive H.
pylori detection methods, including ELISA and the UBT,
has enabled GPs to diagnose and treat H. pylori infection.
The inadequate treatment of peptic ulcer disease results in
therapy failures, high recurrence rates, the emergence of
resistant bacterial strains, and increased health care costs,
therefore clinical application of current knowledge is cru-
cial [13,14].
There are several tests used for diagnosis of H. pylori infec-
tion [12,13,15,16]. 84.4% the GPs surveyed used one or
more tests for H. pylori infection same as Huang J et al.'s
study [6]. However this was higher than reported in a
recently preliminary survey of GPs, of whom 48% used
one or more tests [17]. UBT is the most (44.1%) used tests
in this study. On the other hand, stool antigen test, a use-
ful test for diagnosis, was the least ordered test. It is
Table 1: The Proportions of GPs who would test patients for H. pylori infection in various clinical situations and those who would offer 
treatment based on a positive test (n = 92)
Would you offer testing for H. 
pylori infection
Would you treat H. pylori infection 




n % n % Test Treat
Peptic ulcer 73 79.3 74 80.4 yes yes
New diagnosis of 
duodenal ulcer
67 72.8 73 79.3 yes yes
Past history of 
duodenal ulcer
47 51.1 59 64.1 yes yes
Asymptomatic; 
spouse has H. 
pylori infection
59 64.1 29 31.5 no no
GERD* 38 41.3 50 54.3 no no
Gastric cancer 30 32.6 19 20.7 no no
Patient on long 
term PPI** 
treatment
43 46.7 29 31.5 no no
*GERD = Gastroesophageal reflux disease
** PPI = proton pump inhibitor
Table 2: Treatment regimens
Regimen Number* %
PPI* + clarithromycin + amoxicillin 100 91.7
PPI + clarithromycin + metranidazole 7 6.4
Ranitidine bismuth citrate + clarithromycin + 
amoxicillin or metronidazole, or tetracycline
1 0.9
Ranitidine bismuth citrate + clarithromycin + 
amoxicillin or metronidazole, or 
tetracycline+PPI OR omeprazole
13 11.9
*The total number is higher than the number of the participants for the participants checked more than one item.
** PPI = proton pump inhibitorPage 3 of 5
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the importance of stool antigen test or possibility of usage
of this test. Diagnosis of infection should be done by
using UBT or stool antigen test. It is always recommended
to test by UBT, or endoscopy-based test if endoscopy is
clinically indicated, for successful eradication. On the
other hand stool antigen test is the alternative if UBT is
not available [14].
It is worrisome that considerably fewer perceived a need
for testing and subsequent treatment in patients with a
new diagnosis and past history of duodenal ulcer (Table
1). Both the recent America College of Gastroenterology
(ACG) publications [8] and Centers for Disease Control
and Prevention (CDC) [7] clearly state that a new diagno-
sis and past history of duodenal ulcer disease is a definite
indication for testing and, if positive, for treatment. Test-
ing and treatment of H. pylori infection are recommended
following resection of early gastric cancer and for low-
grade gastric MALT lymphoma. Retesting after treatment
may be prudent for patients with bleeding or otherwise
complicated peptic ulcer disease [7].
Although it is not recommended to test the asymptomatic
individuals for H. pylori infection, 64.1% of GPs reported
that they would offer testing for H. pylori infection and
31.5% of them reported that they would treat H. pylori
infection based on a positive test result in asymptomatic
individuals. These findings suggest that GPs have not suf-
ficient knowledge about the difference between sympto-
matic and asymptomatic individuals. On the other hand,
in any person testing positive for the infection, treatment
may be offered after a full discussion about its potential
risks and benefits [4,18].
Anti-H. pylori therapy was almost never recommended for
suspected ulcer disease without the prior use of diagnostic
tests [13,18]. In this study it was found that 26.6% of GPs
treat the initial onset of a suspected ulcer empirically with-
out ordering diagnostic tests for H. pylori infection. 54.1%
of the GPs, whether ordering diagnostic tests or not,
explain that they send patients with suspected or diag-
nosed H. pylori infection to a specialist. In the light of
these findings, it is thought that GPs preferred to treat the
patients with suspected ulcer, empirically or to send them
to a specialist because of the limited diagnostic condi-
tions, the lack of rapidly diagnostic tests at PHCCs, or they
thought that they should be treated by a specialist.
H. pylori peptic ulcers are treated with drugs that kill the
bacteria, reduce stomach acid, and protect the stomach
lining. Antibiotics are used to kill the bacteria. Two types
of acid-suppressing drugs might be used: H2 blockers and
PPI. H2 blockers and PPI have been prescribed alone for
years as a treatment for ulcers. When used alone, these
drugs do not eradicate H. pylori and, therefore, do not cure
H. pylori-related ulcers. Bismuth subsalicylate, a compo-
nent of Pepto-Bismol, is used to protect the stomach lin-
ing from acid. It also kills H. pylori [4,7,12,19].
The highest eradication rates are achieved with the follow-
ing regimens: a PPI, clarithromycin, and either amoxicil-
lin or metronidazole for 2 week; ranitidine bismuth
citrate, clarithromycin, and either amoxicillin, metronida-
zole, or tetracycline for 2 week; a PPI, bismuth, metroni-
dazole, and tetracycline for 1 to 2 week [7,11,12,20].
There is good evidence for the efficacy of 14-day triple reg-
imens including a PPI or RBC. Possibility of shortening
the duration of PPI-based triple therapies between 7 and
10 days will depend on further results from US-based
studies. Seven-day duration may be too short. Some trials
have failed to show a statistically significant difference in
eradication rates between 7-day and 14-day duration [20].
84.4% GPs test for H. pylori infection but 15.6% never test.
Urea breath test is a commonly used investigative tool for
H. pylori infection. Triple therapy consisting of a proton
pump inhibitor, clarithromycin and amoxicillin is the
most commonly used treatment combination for H. pylori
infection.
It was found that most of the information was being
obtained in traditional teaching formats such as medical
journals, pharmaceutical company-sponsored symposia,
textbooks and conferences. Other studies ([10,13,17])
confirmed our finding that medical journals were the
most important source of information on H. pylori infec-
tion among GPs. Our data suggested that pharmaceutical
company-sponsored symposia were used very frequently
among GPs.
Patients with dyspeptic complaints are mostly managed in
primary care. The most prescriptions for dyspepsia are
empirical without testing due to limitations of diagnostic
facilities around the world [21]. Similar results were
reported that there were significant gaps related to testing
and treating H. pylori infection [13,17].
Conclusions
The diagnosis of and treatment of peptic ulcer disease
related to H. pylori is not adequate. The choice of optimal
therapeutic decision depends on the appropriate defini-
tion of the disease. In order to provide accurate diagnosis
and treatment of H. pylori infection, it's suggested that
efforts to educate the GPs about the algorithms regarding
the management of H. pylori infection during post-gradu-
ation period should be improved in PHCCs.
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